Paule Opolon

Paule Opolon

Auto-generated profile, based on publicly available information

Paule Opolon

Université Paris-Saclay

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JPJuliette Paillet
Juliette Paillet
CPCéleste Plantureux
Céleste Plantureux
SLSarah Lévesque
Sarah Lévesque
JNJulie Le Naour
Julie Le Naour
GSGautier Stoll
Gautier Stoll
JPJonathan POL
Jonathan POL
Cholangiocarcinoma (CCA) results from the malignant transformation of cholangiocytes. Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are chronic diseases in which cholangiocytes are primarily damaged. Although PSC is an inflammatory condition predisposing to CCA, CCA is almost never found in the autoimmune context of PBC. Here, we hypothesized that PBC might favor CCA immunosurveillance. In preclinical murine models of cholangitis challenged with syngeneic CCA, PBC (but not PSC) reduced the frequency of CCA development and delayed tumor growth kinetics. This PBC-related effect appeared specific to CCA as it was not observed against other cancers, including hepatocellular carcinoma. The protective effect of PBC was relying on type 1 and type 2 T cell responses and, to a lesser extent, on B cells. Single-cell TCR/RNA sequencing revealed the existence of TCR clonotypes shared between the liver and CCA tumor of a PBC host. Altogether, these results evidence a mechanistic overlapping between autoimmunity and cancer immunosurveillance in the biliary tract.

14 November 2019 in OncoImmunology
Verified
Journal Article
Open access
AHAnne Sophie Hamy
Anne Sophie Hamy
LDLisa Derosa
Lisa Derosa
CVConstance Valdelièvre
Constance Valdelièvre
SYSatoru Yonekura
Satoru Yonekura
POPaule Opolon
Paule Opolon
FRFabien Reyal
Fabien Reyal
Immunosurveillance plays an important role in breast cancer (BC) prognosis and progression, and can be geared by immunogenic chemotherapy. In a cohort of 1023 BC patients treated with neoadjuvant chemotherapy (NAC), 40% of the individuals took comedications mostly linked to aging and comorbidities. We systematically analyzed the off-target effects of 1178 concurrent comedications (classified according to the Anatomical Therapeutic Chemical (ATC) Classification System) on the density of tumor-infiltrating lymphocytes (TILs) and pathological complete responses (pCR). At level 1 of the ATC system, the main anatomical classes of drugs were those targeting the nervous system (class N, 39.1%), cardiovascular disorders (class C, 26.6%), alimentary and metabolism (class A, 16.9%), or hormonal preparations (class H, 6.5%). At level 2, the most frequent therapeutic classes were psycholeptics (N05), analgesics (N02), and psychoanaleptics (N06). Pre-NAC TIL density in triple-negative BC (TNBC) was influenced by medications from class H, N, and A, while TIL density in HER2+ BC was associated with the use of class C. Psycholeptics (N05) and agents acting on the renin-angiotensin system (C09) were independently associated with pCR in the whole population of BC or TNBC, and in HER2-positive BC, respectively. Importantly, level 3 hypnotics (N05C) alone were able to reduce tumor growth in BC bearing mice and increased the anti-cancer activity of cyclophosphamide in a T cell-dependent manner. These findings prompt for further exploration of drugs interactions in cancer, and for prospective drug-repositioning strategies to improve the efficacy of NAC in BC.

1 October 2001 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
VRVoahangy Randrianarison
Voahangy Randrianarison
DMDidier Marot
Didier Marot
Nicolas ForayNicolas Foray
Nicolas Foray
JCJeannine Cabannes
Jeannine Cabannes
VMVincent Méret
Vincent Méret
JFJean Feunteun
Jean Feunteun

1 November 2003 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
JJJean-Marc Joseph
Jean-Marc Joseph
CBCèline Bouquet
Cèline Bouquet
POPaule Opolon
Paule Opolon
JMJackie Morizet
Jackie Morizet
GAGeneviève Aubert
Geneviève Aubert
GVGilles Vassal
Gilles Vassal

24 September 2009 in Retrovirology
Verified
Journal Article
Open access
PDF file
ADAnne Dupressoir
Anne Dupressoir
CVCécile Vernochet
Cécile Vernochet
OBOlivia Bawa
Olivia Bawa
FHFrancis Harper
Francis Harper
GPGérard Pierron
Gérard Pierron
THThierry Heidmann
Thierry Heidmann

8 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJeremy Rich
Jeremy Rich
MBMelanie Bennaroch
Melanie Bennaroch
LNLaura Notel
Laura Notel
PPPolina Patalakh
Polina Patalakh
JAJulien Alberola
Julien Alberola
IPIryna Pirozhkova
Iryna Pirozhkova
We have recently identified the uncharacterized ZNF555 protein as a component of a productive complex, which is involved in the morbid function of the 4qA locus in facioscapulohumeral dystrophy. As a result of our current findings, ZNF555 is hereinafter referred to as DiPRO1 (Death, Differentiation and PROliferation related PROtein 1). In this study, we provide substantial evidence that DiPRO1 plays a role in human myoblast differentiation. It acts on regulatory binding regions of SIX1, which is a master regulator of myogenesis. We further describe the relevance of DiPRO1 in mesenchymal tumors, such as rhabdomyosarcoma (RMS) and Ewing sarcoma. DiPRO1 plays a repressor role in these tumors via the epigenetic regulators TIF1B and UHRF1 in order to maintain methylation of regulatory cis-elements and promoters. Loss of DiPRO1 eradicates cancer cells, by switching on a distinct transcriptional and epigenetic program. It consists of mimicking the host defense against the virus response by awakening the retrotransposable repeats (RE) and the ZNP/KZFP gene family. DiPRO1 also contributes to the balance of cellular decisions toward inflammation and/or apoptosis by controlling TNF-α via NF-kappaB signaling. Finally, we demonstrate that mesenchymal cancer tumors are vulnerable in response to si/shDiPRO1-based nanomedicines, positioning DiPRO1 as a potential new target for therapeutic intervention. Summary: